Le Lézard
Classified in: Health, Covid-19 virus
Subject: LAW

CDC's Covid-19 Vaccine v-safe Data Released Pursuant to Court Order

AUSTIN, Texas , Oct. 3, 2022 /PRNewswire/ -- In response to a lawsuit filed by Siri & Glimstad LLP on behalf of the Informed Consent Action Network (ICAN), the CDC has released the first set of data from its v-safe program. V-safe is a smartphone-based program created by CDC specifically for Covid-9 vaccines. It allows users to register and provide health check-ins after receiving a Covid-19 vaccine. 

A formal legal request for the v-safe data was submitted to the CDC in June 2021. After two lawsuits were filed on behalf of ICAN, and following months of legal wrangling, the CDC finally capitulated in a court order that required it to produce this data. 

The first set of v-safe data just produced by the CDC pursuant to the court order includes the responses that over 10 million v-safe users provided in v-safe's pre-populated check-the-box fields. 

Out of the approximate 10 million v-safe users, 782,913 individuals, or over 7.7% of v-safe users, had a health event requiring medical attention, emergency room intervention, and/or hospitalization. Another 25% of v-safe users had an event that required them to miss school or work and/or prevented normal activities. 

There were also 71 million symptoms reported in the pre-populated fields. This is an average of more than 7 symptoms reported per v-safe user. Reported symptoms include, for example, over 4 million reports of joint pain. While around 2 million of these joint pain reports were mild, over 1.8 million were for moderate joint pain and over 400,000 were for severe joint pain. It is noted that v-safe includes data from less than 4 percent of individuals who received a Covid-19 vaccine in the United States.  

There were also around 13,000 infants under 2 years of age registered in v-safe. Among these infants, over 33,000 symptoms were reported, with the most common symptoms being irritability, sleeplessness, pain, and loss of appetite. 

The data also reflects a disproportionate amount of negative health impacts, including medical events, following the Moderna vaccine versus the Pfizer vaccine and shows a disproportionate number of negative events reported by women versus men. 

Since the data is voluminous, ICAN has generated a v-safe dashboard to present it in a user-friendly format for the public. This v-safe dashboard can also generate the statistics noted above and is available at www.icandecide.org/v-safe-data/.

V-safe provides users with a limited number of fields to choose from when reporting health events as well as free-text fields. The data produced thus far is limited to the pre-populated fields within v-safe. Siri & Glimstad's attorneys leading these lawsuits, Aaron Siri and Elizabeth A. Brehm, will continue to litigate to obtain the data submitted by v-safe users in the free-text fields.

SOURCE Siri & Glimstad LLP

These press releases may also interest you

26 nov 2022
A study in the journal BMJ Global Health found that mothers who were exposed to a lot of digital marketing were less likely to breastfeed their babies for the first six months of their lives and more likely to give them processed foods and sugary...

25 nov 2022
Vaccine candidate has the potential to be the first available to help protect adults aged 60 years and older from lower respiratory tract disease caused by respiratory syncytial virusApplication includes important pivotal phase III data evaluating...

25 nov 2022
Summary Brand: LebbyProduct: Dark Chocolate Chickpea SnacksCompanies: Ecoideas Innovations Inc.Issue: Food ? Allergen ? MilkCategory: Candy, confectionary, snacks and sweetenersWhat to do: Do not consume recalled products to which you are allergic or...

25 nov 2022
It's easy to find personal training in New Braunfels, Texas, but it's difficult to find someone that's committed and focused on your goals. Health Yourzelf is the leader in personal training in the Comal County region. Led by Matt Zampas, he...

25 nov 2022
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, has received notification from the Nasdaq Stock Market LLC Listing...

25 nov 2022
IMV Inc. ("IMV" or the "Company") , a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that, on November 22, 2022, the Company...

News published on 3 october 2022 at 20:09 and distributed by: